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Abstract
Background: Most studies have found no increased risk of colon cancer associated with hormone
replacement therapy (HRT), or even a decreased risk. But information about the effects of different
HRT preparations is lacking.
Methods: A case-control study was performed within Germany in collaboration with regional
cancer registries and tumor centers. Up to 5 controls were matched to each case of colon cancer.
Conditional logistic regression analysis was applied to estimate crude and adjusted odds ratios
(OR) and 95% confidence intervals (95% CI). Stratified analyses were performed to get an
impression of the risk associated with different estrogens and progestins.
Results: A total of 354 cases of colon cancer were compared with 1422 matched controls. The
adjusted overall risk estimate for colon cancer (ColC) associated with ever-use of HRT was 0.97
(0.71 – 1.32). No clinically relevant trends for ColC risk were observed with increasing duration
of HRT use, or increasing time since first or last HRT use in aggregate.
Whereas the overall risk estimates were stable, the numbers in many of the sub-analyses of HRT
preparation groups (estrogens and progestins) were too small for conclusions. Nevertheless, if the
ColC risk estimates are taken at face value, most seemed to be reduced compared with never-use
of HRT, but did not vary much across HRT formulation subgroups. In particular, no substantial
difference in ColC risk was observed between HRT-containing conjugated equine estrogens (CEE)
or medroxyprogesterone acetate (MPA) and other formulations more common in Europe.
Conclusion: Ever-use of HRT was not associated with an increased risk of colon cancer. In
contrary, most risk estimates pointed non-significantly toward a lower ColC risk in HRT ever user.
They did not vary markedly among different HRT formulations (estrogens, progestins). However,
the small numbers and the overlapping nature of the subgroups suggest cautious interpretation.
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Background
Complex discussions surrounding the role of steroid hor-
mone formulations, particularly concerning Hormone
Replacement Therapy (HRT), experienced a revival after
the publication of the Women's Health Initiative (WHI)
Study in 2002 [1].
Many earlier studies reported no significant increase in
colon cancer for ever-use of HRT, and more often a
decreased risk [2,3]. The two arms of the WHI studies [1,4]
reported a risk of colon cancer associated with HRT use
around unity, and non-significantly reduced, respectively.
The HERS studies [5] reported similar findings. However,
these results are based on preparations with CEE (conju-
gated equine estrogens) or CEE plus MPA (medroxypro-
gesterone acetate) and almost nothing is known about the
colon cancer risk associated with different HRT prepara-
tions and ways of application.
The primary aim of this publication is to present data on
colon cancer risk associated with use of different HRT for-
mulations and administrations.
Methods
The study method has been recently described in greater
detail elsewhere [6]. In brief: The objective of this study is
to analyze possible differences in the risk of colon cancer
(ColC) associated with different HRT formulations, using
a case-control design, i.e. in collaboration with German
cancer registries and tumor centers (see acknowledge-
ments).
The lifetime history of exposure to sex steroid hormones
was recorded by month and year of exposure (type, brand
name). This information was compiled primarily on the
basis of a questionnaire. Relevant approvals of the study
were obtained (Ethical Committees; Office of Data Pri-
vacy).
Eligible cases were histologically confirmed malignant
neoplasms of the colon (ICD 10: C18; in accordance with
the definition of the IARC Cancer Registry [7]) diagnosed
mainly between 2000 and 2004 in women of all age
groups. Subjects had to be alive, in sufficiently good
health, and willing to complete the questionnaire.
A potential total of 354 cases was included in the analysis.
Up to five controls were matched for each ColC case,
using the same age (year of birth +/- two years) and resi-
dency (Bundesland) as matching criteria. A pool of poten-
tial controls from a large cohort study was used – as
described in a previous publication 6. We found 1422
matched controls for 354 ColC cases.
Data collection, variables and database preparation
Time-related information on lifetime history of hormone
use as well as data on reproductive life, lifestyle pattern,
conditions/diseases, and some other factors were
obtained via a self-administered postal questionnaire.
HRT preparations ever used were classified according to
the route of administration (oral, transdermal, other),
type of combination (sequential, continuous-combined),
estrogen type (estradiol, and conjugated equine estrogens
(CEE)), and progestin type (Noretisterone acetate
(NETA), Levonorgestrel (LNG), Medroxyprogesterone
acetate (MPA), Medrogestone, and Tibolone); the num-
bers for other progestins were too small for calculating
risk estimates).
Each participant who had ever used HRT in more than one
of the above HRT categories was counted more than once
across the analyses (depending on switching pattern), i.e.
the categories are notmutually exclusive. Therefore, com-
parison of risk estimates across exposure groups can be
used only as a first impression as to whether there are sub-
stantial differences or not. We also refrained from defin-
ing categories of HRTs in terms of "longest used during
lifetime", because of the arbitrary character of the decision
as well as the assumed incompatibility for what "longest"
might mean across different compounds.
Index dates
We excluded stepwise information on exposure close to
the date of diagnosis, because we cannot exclude the pos-
sibility that prior to the final diagnosis of colon cancer,
the women and/or their physicians might have been
aware of "warning signs" (e.g., history of polyps) that may
have led to a decision to start HRT or not previously. A
series of index dates was introduced, such as 0.5, 2, 4, and
6 years, i.e. all exposure-related information between
these dates and the date of diagnosis was ignored in the
respective analyses. We intended to estimate the possible
magnitude of such a bias if it exists. In this report, we
focus on a lag-time of 0.5 year prior to diagnosis in order
to avoid the effects of decisions related to a perceived
ColC risk in the time immediately preceding the cancer
diagnosis.
The analytic model
Conditional logistic regression was used as primary anal-
ysis. Crude and adjusted odds ratios (OR) were reported
with 95% confidence intervals (95% CI). Adjustment var-
iables were BMI, family history of colon cancer, child-
bearing history, age at first live birth, duration of breast-
feeding, age at menarche, OC use, and education,
whereby missing values were imputed (modal value) to
allow the analysis. For sub-group analyses of HRT catego-
ries, we additionally adjusted for age and residencyBMC Cancer 2007, 7:76 http://www.biomedcentral.com/1471-2407/7/76
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because the matching effect was lost in the individual sub-
groups. We were not able to use age at menopause as a co-
variable because it could not be reliably determined for a
high proportion of participants. Moreover, we refrained
from complex adjustment in these subgroup analyses to
prevent unstable risk estimates. For the same reason, we
did not calculate risk estimates if any cell of the "two-by-
two" table contained fewer than 5 women.
We analyzed the impact of duration of HRT as well as time
since first and last HRT use for each of four categories. The
statistical packages SAS 9.1 and STATA 8.0 were used.
Results
Case/non-case characteristics
Table 1 compares the colon cancer cases with the matched
controls concerning a list of risk markers and potential
confounders. The mean ages of the cancer cases and
matched controls were similar (matching).
However, increasing age was significantly associated with
increased risk of colon cancer, i.e. both as a continuous
(OR = 1.64 per year) and a dichotomized categorical var-
iable (OR = 4.38), as was first-degree family history of
colon cancer (OR = 3.40). Significantly reduced ColC risk
was observed for higher education (OR = 0.64).
Higher number of children (OR = 0.75 per child), ever
breast-feeding (OR = 0.31), and ever-use of oral contra-
ceptives (OR = 0.64) were apparently associated with
lower ColC risk. However, the association with HRT use
was marginal only, i.e. the effect as confounder negligible.
Table 1: Description of cancer cases and controls and their potential as risk factors for colon cancer.
No. cases1 No. controls1 Adj. OR (95% CI)
Age (continuous) per year 354 1422 1.64 (1.52–1.77)
Age < 50 years 47 249 referent
50+ years 307 1173 4.38 (1.41–13.62)
Education Lower education 279 1014 referent
University level 64 394 0.64 (0.45–0.91)
Age at menarche (cont) per year 344 1396 1.04 (0.95–1.14)
Age at menarche < 13 years 148 683 referent
13+ years 196 713 1.16 (0.87–1.55)
Pregnancy Never pregnant 32 104 referent
Ever pregnant 318 1300 0.85 (0.50–1.45)
Number of children (cont) per child 318 1286 0.75 (0.64–0.89)
Age at first live birth (cont) per birth 316 1274 1.00 (0.96–1.04)
Age at first live birth < = 22 years 140 624 referent
> 22 years 176 650 1.15 (0.84–1.57)
Breast-feeding never 193 525 referent
ever 157 878 0.31 (0.23–0.43)
OC use never 144 484 referent
ever 210 933 0.64 (0.46–0.89)
Family history of colon 
cancer
No 192 656 referent
Yes 68 54 3.40 (2.08–5.56)
BMI (cont) 348 1406 0.96 (0.93–0.99)
Body mass index < 25 135 505 referent
25+ 213 901 0.91 (0.68–1.23)
1 Differences in numbers of cases/controls across variables are due to missing information
Conditional logistic regression: Age-adjusted odds ratios (OR) and 95% confidence intervals (CI).BMC Cancer 2007, 7:76 http://www.biomedcentral.com/1471-2407/7/76
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The result for BMI showed a slight decrease with increas-
ing BMI (marginally significant in the analysis as continu-
ous variable). All other factors listed in Table 1 showed no
statistically significant decreased or increased risk.
All the above variables were significant effect modifiers of
the association between HRT exposure and ColC risk
(data not shown) and therefore included in the analyses
to control for confounding, but had a marginal effect only
(compare crude and adjusted ORs in the following
tables).
Ever vs. never-use of HRT
Table 2 presents no increased risk of colon cancer in HRT
users compared with never users (adj. OR 0.97; 95% con-
fidence interval 0.71 to 1.30) at the index date of 0.5 year.
The risk estimates did not vary markedly across all other
index dates (data not shown in table 2) and were very sim-
ilar with and without adjustment.
Stratified analyses
Table 2 also shows results of the analyses stratified by
duration of HRT use, time since first HRT use and time
elapsed since last HRT use. Neither longer duration of
HRT use nor longer time since first or last use showed
meaningful differences in colon cancer risk when ana-
lyzed in aggregate, i.e. not considering specific HRT sub-
groups. Most risk estimates were below unity (1.0) but
without statistical significance (however the statistical
power of these sub-analyses was low in some subgroups).
A significant trend of ColC risk with increasing time was
not observed.
Cancer risk across different HRT formulations
Table 3 provides ColC risk estimates (and 95% confidence
intervals) for the index date of 0.5 year by HRT formula-
tions. In addition, the table is stratified by duration of use
– to the extent numbers permitted ("rule of 5 per cell" –
see methods section). It must be stressed again that the
HRT categories are not mutually exclusive, except the
three categories of CEE/MPA combination but here again
with small numbers of exposed cases.
Ever-use of HRTs via oral and transdermal routes of
administration showed no significant association with
colon cancer in aggregate, but there was a significantly
increasing trend with longer duration of use. The latter
was not observed for the other routes of administration
but the numbers were tiny.
Both sequential and continuous combined formulations
showed virtually identical, non-significantly reduced
ColC risk estimates in aggregate. An increasing trend of
risk with increasing duration of use was found for sequen-
tial formulations but not for continuous-combined,
although the confidence intervals were largely overlap-
ping and the numbers in the strata for duration small in
continuous-combined HRTs. This was similar for the
Table 2: Risk of colon cancer and HRT use: Ever-use of HRT vs. never-use.
e-case1 e-ctrl.1 Adj. OR (95% CI)
Ever HRT 150 562 0.97 (0.71–1.32)
Duration of use2,3
1–4 yrs 22 130 0.65 (0.37–1.16)
5–9 yrs 41 180 1.06 (0.67–1.68)
10+ yrs 45 175 0.87 (0.53–1.41)
Time since first use2,3
1–4 yrs 41 148 1.04 (0.66–1.66)
5–9 yrs 46 193 0.99 (0.64–1.52)
10–14 yrs 36 133 1.04 (0.65–1.69)
15+ yrs 27 88 0.79 (0.45–1.39)
Time since last use2,3
< 1 yr/current use 136 496 1.00 (0.74–1.38)
1–2 yrs 8 43 0.72 (0.31–1.69)
3–4 yrs 5 22 0.85 (0.29–2.50)
5+ yrs 1 1 n.d.4
1 e-case, e-ctrl = number of observations for exposed cases or exposed controls respectively.
2 time variables were rounded
3 no significant trend with increasing time
4 n.d. = no data
Conditional logistic regression analysis [odds ratios (OR) and 95% confidence intervals]; adjustment for BMI, family history of colon cancer, 
childbearing history, age at first live birth, duration of breast-feeding, age at menarche, ever OC use, education. Index dates 0.5 = exposure 
information was not considered 0.5 years prior to cancer diagnosis.BMC Cancer 2007, 7:76 http://www.biomedcentral.com/1471-2407/7/76
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Table 3: Risk of colon cancer associated with different categories of HRT formulation or administration.
e-case/e-ctrl Adj. OR (95% CI)
Route of administration
ORAL
Ever 99/381 0.76 (0.54–1.08)
1–4 years 17/108 0.54 (0.30–1.00)
5–9 years 27/125 0.61 (0.36–1.04)
10+ years 38/103 1.14 (0.68–1.92)
TRANSDERMAL
Ever 24/99 1.17 (0.63–2.16)
1–4 years 6/29 0.98 (0.34–2.86)
5–9 years 5/32 0.87 (0.30–2.51)
10+ years 10/27 2.16 (0.73–6.36)
OTHER
Ever 11/48 0.96 (0.40–2.31)
1–4 years 1/11 n.d.
5–9 years 2/11 n.d.
10+ years 5/19 1.15 (0.30–4.35)
Form of combination
SEQUENTIAL FORMULATIONS
Ever 46/191 0.80 (0.51–1.20)
1–4 years 5/49 0.47 (0.17–1.31)
5–9 years 14/66 0.66 (0.32–1.35)
10+ years 22/50 1.45 (0.70–3.04)
CONTINUOUS-COMBINED
Ever 40/176 0.80 (0.50–1.29)
1–4 years 8/53 0.66 (0.26–1.66)
5–9 years 12/52 0.56 (0.25–1.20)
10+ years 9/47 0.65 (0.26–1.67)
ANY COMBINATION
Ever 78/324 0.85 (0.59–1.21)
1–4 years 13/94 0.56 (0.28–1.12)
5–9 years 23/104 0.71 (0.40–1.24)
10+ years 28/83 1.21 (0.67–2.21)
CEE/MPA combinations
CEE + MPA
Ever 3/27 n.d
1–4 years 0/9 n.d.
5–9 years 1/7 n.d.
10+ years 1/10 n.d.
CEE or MPA
Ever 42/142 0.64 (0.38–1.10)
1–4 years 6/36 0.44 (0.16–1.20)
5–9 years 13/46 0.63 (0.26–1.52)
10+ years 20/45 1.10 (0.49–2.47)
No CEE, no MPA
Ever 80/306 0.95 (0.66–1.37)
1–4 years 19/89 0.87 (0.48–1.59)
5–9 years 21/104 0.78 (0.44–1.38)
10+ years 21/73 1.11 (0.58–2.13)BMC Cancer 2007, 7:76 http://www.biomedcentral.com/1471-2407/7/76
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Formulation content
ONLY – HRTS
ESTROGEN ONLY
Ever 55/189 0.81 (0.51–1.28)
1–4 years 8/46 0.50 (0.20–1.24)
5–9 years 14/66 0.98 (0.47–2.06)
10+ years 25/60 1.07 (0.52–2.19)
PROGESTAGEN ONLY
Ever 9/35 0.48 (0.17–1.37)
1–4 years 1/10 n.d.
5–9 years 2/9 n.d.
10+ years 6/12 0.57 (0.13–2.48)
Estrogen type
ESTRADIOL (E2)
Ever 80/350 0.86 (0.60–1.22)
1–4 years 16/99 0.73 (0.39–1.36)
5–9 years 22/112 0.89 (0.52–1.54)
10+ years 28/92 1.10 (0.62–1.91)
CONJUGATED EQUINE ESTROGENS 
(CEE)
Ever 40/141 0.70 (0.41–1.19)
1–4 years 5/35 0.44 (0.16–1.25)
5–9 years 12/47 0.61 (0.25–1.49)
10+ years 19/49 1.30 (0.57–2.73)
Progestin type
NORETISTERONE ACETATE (NETA)
Ever 42/193 0.78 (0.48–1.25)
1–4 years 7/57 0.54 (0.20–1.44)
5–9 years 13/61 0.73 (0.35–1.53)
10+ years 14/49 0.90 (0.42–1.94)
LNG
Ever 22/83 0.88 (0.46–1.68)
1–4 years 2/21 0.45 (0.10–2.08)
5–9 years 6/35 0.53 (0.19–1.49)
10+ years 9/19 1.64 (0.51–5.30)
MEDROXYPROGESTERONE ACETATE 
(MPA)
Ever 8/55 0.42 (0.16–1.10)
1–4 years 1/19 n.d.
5–9 years 3/13 n.d.
10+ years 3/16 n.d.
MEDROGESTONE
Ever 18/65 0.87 (0.43–1.73)
1–4 years 3/17 n.d.
5–9 years 4/23 n.d.
10+ years 10/19 1.81 (0.62–5.28)
TIBOLONE
Ever 5/14 0.91 (0.26–3.23)
1–4 years 2/6 n.d.
5–9 years 0/3 n.d.
10+ years 3/4 n.d.
The categories are not mutually exclusive – (see text). Ever use and three categories of duration of use in years are presented.
Conditional logistic regression: Odds ratios (OR) and 95% confidence intervals (95% CI); adjusted for age and region. No OR was calculated if the 
frequency of exposed cases or controls was fewer than 5 women. The only index date shown in this table is 0.5 years.
e-case/e-ctrl = number of exposed cases and controls, respectively
Table 3: Risk of colon cancer associated with different categories of HRT formulation or administration. (Continued)BMC Cancer 2007, 7:76 http://www.biomedcentral.com/1471-2407/7/76
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respective subgroups of duration of use, taking the over-
lapping confidence intervals into account. This was also
true for all estrogen + progestin combinations together.
The seemingly increasing risk estimates with longer dura-
tion of use in the subgroup of sequential formulations, for
example, showed largely overlapping confidence inter-
vals, as can also be seen for other trends with increasing
duration of use.
No obvious or meaningful difference in risk for ColC was
found between ever-use of CEE and ever-use of MPA;
however, the numbers were too small for the fixed combi-
nation of CEE plus MPA.
No meaningful difference in ColC risk was observed
between ever-use of estrogen and ever-use of progestin-
only formulations, although the numbers for progestin
only were too small for meaningful analysis.
A risk of ColC was not significantly associated with either
of the two analyzable estrogens, i.e. it was similar and at
least not increased (largely overlapping confidence inter-
vals).
Of the progestins, only NETA, LNG, MPA, Medrogestone,
and to some extend also Tibolone showed mainly non-
significantly decreased ColC risk estimates if taken at face
value. Many of the subgroups for duration of use were too
small to permit meaningful calculations.
Discussion
Colorectal cancers altogether are the fourth most com-
mon cancer worldwide and commonly thought to be
associated with food and nutrition – except for genetic
risk and polyposis – as recently expressed by an expert
committee from the American Institute for Cancer [8].
We observed other potential risk markers for colon cancer
beyond food and nutrition in our case-control study (see
table 1). The observation that increasing age as well as
family history significantly increases the risk of colon can-
cer is not new and is shared by the literature. But less com-
mon is the observation that many variables associated
with reproductive history reduce the ColC risk, such as
higher number of children, breast-feeding, and a history
of OC use. And these markers are considered to be associ-
ated with sex-steroid hormone use, i.e. included in the
analysis as confounding variables.
We abstain from a detailed discussion of the impact of
above variables of reproductive history on lower risk of
ColC, because it was not the objective of our study to
answer such questions with relative small numbers and
other limitations of the study (see later). Like OC ever-use,
information on reproductive history was obtained in a
search for differences between cases and controls that pos-
sibly could explain different risk of HRT user (potential
confounding). Although OC ever-use is closer to the
research question of an effect of HRT on colon cancer risk,
the study was not designed to analyse the impact of OCs
on ColC. Fortunately – taken at face-value – the point esti-
mates of OC use and HRT use (irrespective of formula-
tion) point in a similar direction, i.e. toward lower risk of
colon cancer, but mainly non-significant.
The above-mentioned expert panel from the American
Institute for Cancer did not assign external sex-steroid
hormones a convincing role among important risk factors
[8]. On the other hand, the possibility that sex-steroid
hormones might play a role cannot be ignored and are
debated for years. Estrogen receptors are present in the
colon and estrogen-mediated changes to the receptor
could be compatible with a decrease in ColC risk. Methyl-
ation of DNA is a hot issue in colon cancer genesis and can
be discussed as biological plausibility of reduced ColC
risk associated with hormone (estrogen) use [9,10].
Most but not all of the previously published epidemiolog-
ical studies on colon cancer in women found a reduced
risk associated with external use of sex-steroid hormones
[11]. A review by Franceschi and La Vecchia [2] reported
that an inverse association between colon cancer and HRT
use was described in 5 of 12 case-control studies with a
20–40% risk reduction; the remaining studies also
observed inverse but non-significant associations with
HRT use – like in our case-control study. Other cohort
studies showed relative risks around or below unity. The
information concerning the effect of duration of use and
other time-dependent variables differed across studies – if
reported at all. In a review and meta-analysis of 18 epide-
miological studies, Grodstein [3] found a 20% reduction
in ColC risk associated with postmenopausal HRT use
(compared with never-use). The discussion suggested that
observed differences could be due to different user pat-
terns or types of HRT or just a chance finding notwith-
standing the often discussed problem of statistical
significance and clinical relevance. The authors of this
review stressed that biological evidence supports such an
inverse association and found it similar to the observa-
tions made regarding oral contraceptives. Even clinical tri-
als have recently reported no or a non-significantly
reduced risk of colon cancer, namely the HERS-studies
(HR = 0.81) [5] and the WHI studies (HR = 0.63 ns in E+P
arm; HR = 1.08 ns in E-only arm) [1,4]. These findings are
compatible with the results of our observational study:
Overall, non-significant association around or below
unity between colon cancer and HRT use compared with
never-use. We found a non-significant reduction in the
risk of ColC for most HRT subgroups. The small numbersBMC Cancer 2007, 7:76 http://www.biomedcentral.com/1471-2407/7/76
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for subgroups of HRT formulations and the subsequently
large confidence intervals preclude strong conclusions.
The distribution of ColC risk estimates for different HRT
formulation categories is compatible with the notion that
no obvious differences were observed. All point estimates
were non-significantly around or below unity (1.0). Taken
at face value, some point estimates for HRT use would be
compatible with a decreased risk of colon cancer. The
largely overlapping confidence intervals across various
HRT formulation groups argue strongly against convinc-
ing differences. The interpretation of the statistically sig-
nificant trend of increasing risk estimates with increasing
duration of use in some but not all HRT subgroups – in
contrast to no significant risk trend of duration of HRT use
in aggregate – is not clear. This might be a biased or ran-
dom observation or real, important or clinically meaning-
less. At least we cannot explain this finding and would
hesitate to draw any clinical conclusions from it unless it
is confirmed in other studies, i.e. particularly in absence of
evidence for an increased ColC risk.
Limitations of the study
It is a shortcoming of our study that we had small num-
bers of cases in many of the interesting sub-analyses, and
thereby were not able to detect significant differences in
colon cancer risk according to different hormone prepara-
tions or ways of administration.
Analysis of the effect of external hormones on colon can-
cer must take into account the lag time in cancer develop-
ment, although it is difficult for observational studies to
account sufficiently for time-dependence. Lag time is
likely to be long and may vary depending on complex
unknown causal mechanisms, and is therefore an issue
involving complex, time-dependent risk factors. Moreo-
ver, even observational studies with "state-of-the-art" per-
formance face an important methodological problem if
the observed risk estimates are small. Given the great
potential for residual confounding and different forms of
bias, even a statistically significant small positive or
inverse association cannot be ruled out and the results
might be inconclusive. Such small associations could well
be situated below reliable resolution levels of the "epide-
miological microscope", i.e. it is not possible to differen-
tiate between causation and bias/confounding [12,13].
We assume that the results of our study have not been sub-
stantially affected by differential surveillance or preven-
tion bias, self-selection or recall bias, although we cannot
exclude these possibilities. Another potential source of
bias is diagnostic suspicion bias. Nobody can be sure that
tumor cases are equally identified (diagnosed) among
HRT users and non-users. This, however, would not
explain the low point estimates of ColC risk observed, i.e.
this would be a conservative estimate.
Despite some advantages of our study over many others in
considering time-dependent exposure during the lifetime,
or in introducing different lag times to perform stratified
analyses, we do not know the impact of the above-men-
tioned biases on the observed risk estimates. Therefore,
our interpretation of the ColC risk estimates observed in
the case-control study should be taken with care.
Conclusion
Our study together with the available literature supports
the notion that use of HRT is not associated with an
increased risk or even the possibility of an inverse associ-
ation between colon cancer and HRT use. Obviously, the
observed risk did not vary markedly among different HRT
formulations (estrogens, progestins). However, the small
numbers and the overlapping nature of some of the sub-
groups suggest cautious interpretation. In addition, there
might be differences that were not detectable in our study
due to the "limited resolution of the epidemiological
microscope". And finally, residual confounding and bias
cannot be ruled out.
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